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Abstract  29 
A major endeavour of systems biology is the construction of graphical and computational models of 30 
biological pathways as a means to better understand their structure and function. Here, we present a 31 
protocol for a biologist-friendly graphical modelling scheme which facilitates the construction of detailed 32 
network diagrams, summarising the components of a biological pathway (such as proteins, biochemicals 33 
etc.) and how they interact. These diagrams can then be used to simulate activity flow through a pathway, 34 
thereby modelling its dynamic behaviour. The protocol is divided into four sections: 1) Assembly of 35 
network diagrams using the modified Edinburgh Pathway Notation (mEPN) scheme and yEd network 36 
editing software using pathway information obtained from published literature and databases of molecular 37 
interaction data, 2) parameterisation of the pathway model within yEd through the placement of ‘tokens’ 38 
based on the known or imputed amount or activity of a component, 3) model testing through visualization 39 
and quantitative analysis of the movement of tokens through the pathway using network analysis tool 40 
BioLayout Express3D, 4) optimisation of model parameterisation and experimentation. This is the first 41 
modelling approach that combines a sophisticated notation scheme for depicting biological events at the 42 
molecular level, with a Petri net-based flow simulation algorithm and powerful visualisation engine with 43 
which to observe the dynamics of the system being modelled. Unlike many mathematical approaches to 44 
modelling pathways, it does not require the construction of a series of equations or rate constants for 45 
model parametrisation. Depending on a model’s complexity and the availability of information, its 46 
construction can take days to months, and, with refinement, possibly years. However, once assembled 47 
and parameterised, a simulation run, even on a large model, typically takes only seconds. Models 48 
constructed using this approach provide a means of knowledge management, information exchange, and 49 
through the computation simulation of their dynamic activity, a means to generate and test hypotheses, 50 
and predict a system’s behaviour when perturbed.  51 
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Introduction 52 
The era of molecular biology has resulted in the generation of vast amounts of data on biological 53 
processes, ranging from in-depth studies of one or two molecules and their interactions, to large sets of 54 
omics data. These data are currently scattered in the literature and databases and difficult to connect 55 
together. Those trying to learn about a particular biological process or pathway often start by studying the 56 
primary literature and reviews. However, relying only on the medium of the written word it can often be a 57 
struggle to understand the available knowledge as a series of interconnected events. The task is made 58 
more difficult as the literature often refers to the same pathway component by different names, which may 59 
not or not be their official names (as dictated by nomenclature committees). Representation of biological 60 
systems as graphical models, i.e. diagrams, can in principle circumvent these issues by presenting a 61 
system in a visually intuitive manner using a standardized notation scheme to represent pathway 62 
components and the interactions between them. One of the ultimate goals of a pathway model is the 63 
ability to use it for computational simulations, thereby supporting hypothesis generation and experimental 64 
design. Use of a system that fulfils these criteria could benefit any scientist working in experimental 65 
biology.  66 
 67 
We have developed a modelling platform that combines elements of other approaches1. The modified 68 
Edinburgh Pathway Notation (mEPN) scheme was first published in 20082, refined in 20103, and is 69 
presented here in its current form (BOX 1).  Representing the interactions between biological components 70 
in the context of a pathway diagram is a challenge, and a number of notation schemes have been 71 
proposed3-9. In an effort to standardise pathway diagrams, the Systems Biology Graphical Notation 72 
(SBGN) community proposed standards for pathway depiction, including the process description (PD) 73 
language7 based on ideas first proposed by Kitano et al.4. In SBGN-PD diagrams (and in the modelling 74 
approach described here), components of a pathway are depicted using a standard set of shapes 75 
(glyphs), and both the nature of the interactions between components and the products of those 76 
interactions must be shown explicitly. Pathway models are constructed where entity nodes represent 77 
molecular components, process nodes represent the different types of interactions that can occur 78 
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between the components, and edges link entity and process nodes. Since PDs were first described 79 
various models have been constructed based on this approach2,10-15 and there is a growing number of 80 
software tools that support model creation (using SBGN-compliant languages), e.g., CellDesigner16,17, 81 
NaviCell11, KEGG Mapper18, ReactomeFiViz19, iPath20 and SBGN-Ed21. There are also a number of 82 
centralised databases providing pathway resources of this type22-25. The mEPN scheme used here to 83 
model pathway systems is similar to the SBGN ‘process description language’ but with important 84 
differences in how both components and events are represented. In particular, mEPN supports the 85 
representation of a wider variety of biological components and processes, simplifies the depiction of 86 
complexes, promotes the use of standard nomenclature, and importantly, diagrams can be used directly 87 
for the computational modelling of system dynamics (for a more complete description of mEPN and 88 
comparison to the SBGN-PD language, see O’Hara 20161). mEPN pathway models can be drawn using 89 
the free graph editing software yEd (yWorks, Tübingen, Germany; www.yworks.com), and since the 90 
notation scheme was first described 2,3 has been formalised so as to support the use of models for 91 
pathway activity simulations1.  92 
Numerous mathematical approaches exist to simulate system dynamics including ordinary and partial 93 
differential equations, qualitative differential equations and stochastic equations. The Systems Biology 94 
Markup Language (SBML) has been developed as an open interchange format for such mathematical 95 
models26 and the SBML site also has an extensive list of existing tools and resources supporting pathway 96 
modelling primarily by equation-based approaches 97 
(http://sbml.org/SBML_Software_Guide/SBML_Software_Summary). Most mathematical models require 98 
experimentally derived rate constants to feed into equations and significant computational power to solve 99 
a series of equations. This generally limits equation-based approaches to modelling relatively small and 100 
well characterised systems. Moreover, the level of mathematics skills required to construct and run these 101 
models is often a deterrent to adoption by biologists. The platform described here uses Petri nets, as the 102 
basis for pathway activity simulations. The primary resource for Petri net modelling is a network diagram 103 
consisting of nodes, called ‘places’, and other nodes representing the interactions between them, called 104 
‘transitions’, to which the user need only add ‘tokens’, that represent the amount or activity of a place prior 105 
to performing a simulation (for more details of Petri nets see BOX 2). There is a long and established 106 
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precedent for the use of Petri nets in the modelling of biological pathways 27-33 and several tools and 107 
algorithms are available that allow the user to construct models based on Petri nets 34-36. The Petri net 108 
algorithm employed here was first described by Ruths et al.37 who named their approach the signalling 109 
Petri net simulator (SPN). It combines elements of a Boolean network simulator38 with a synchronized 110 
Petri net model39, and models the stochastic flow of tokens through a network. A great advantage of Petri 111 
nets is the relative ease of model parameterisation, the scale to which models can be constructed, the 112 
computational speed of simulations, as well as the fact that the user does not need to directly modify the 113 
maths when experimenting. The downside to most of the tools that currently support pathway modelling 114 
using Petri nets is the inability to represent pathway models in anything but the standard Petri net notation 115 
(open circles and black rectangles), and limited options for the visualization of results. Here, we describe 116 
how a pathway model drawn according to the rules of mEPN, can then be parameterised for 117 
computational modelling by the addition of tokens, whose quantity can be based on experimental results 118 
such as quantitative transcriptomics or proteomics data. When a mEPN model is imported into the open-119 
source software BioLayout Express3D 40 it is visualised in a 3D environment, with nodes now represented 120 
as 3D shapes. Simulations can subsequently be performed that calculate the flow of tokens through the 121 
pathway over time. Pathway activity can then be visualised as plots or animations, where token 122 
accumulation is represented by the size and colour of an entity node (Supplementary Video 1). Altering 123 
the simulation parameters can change the flow of tokens, allowing the dynamics of pathways to be 124 
modelled under different conditions. The modelling approach described in this protocol can be applied to 125 
model any system, large or small, biological or otherwise, that consists of a series of components that 126 
interact in a predefined manner. In the case of biological pathways, the mEPN notation scheme allows for 127 
the detailed representation of signalling cascades, metabolic pathways, transcriptional networks, as well 128 
as feedback/feedforward loops. To date, we have used this approach to model a wide variety of biological 129 
pathways, particularly associated with immune signalling, e.g., Toll-like receptors (TLR), NF-kB, 130 
complement activation and antigen presentation, but also biochemical pathways e.g. cholesterol 131 
metabolism, TCA cycle, and even pathways spanning multiple organ systems e.g. glucocorticoid, 132 
oxytocin/prolactin signalling (see: www.virtuallyimmune.org and O’Hara et al.1 for examples). Many of 133 
these models were built as graphical representations of events as described in the literature and as such 134 
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act as a graphical bibliography, with pathway components or processes hyperlinked to research papers or 135 
reports. However, with additional work they can also be used as the basis for performing simulation 136 
experiments. These simulations not only test the logic of what is depicted, but also predict the behaviour 137 
of the system and its response to perturbation. Using this approach models can be assembled at scale, 138 
representing tens or thousands of components and the interactions between them. The overall aim of the 139 
modelling approach described here is to, provide a platform for the assembly of information on a 140 
particular system into an informative diagram, to allow the use of the diagram explore how the system 141 
might operate, and through experimentation, make testable predictions 41 42. 142 
The protocol provided here complements the paper published recently by O’Hara et al.1, which describes 143 
the development of and underlying concepts associated with this approach. This modelling platform may 144 
not be appropriate in situations where many of the interactions between components are not known due 145 
to the requirement to define both components and interactions, or where there is need to use specific rate 146 
parameters to regulate the dynamics of a system, as the approach does not allow for the integration of 147 
rate constants for specific reactions. Other limitations of Petri net-based approaches are the requirement 148 
that all tokens and transitions behave the same way. In other words how a protein binding event is 149 
modelled, is the same as how an enzymatically catalysed biochemical reaction would be modelled, where 150 
outputs are determined by the number of tokens on the reactants. This is not likely to be an issue for 151 
many applications, but could limit the approach’s applicability in certain circumstances requiring more 152 
complicated concepts to be built within the model. 153 
 154 
Experiment Design 155 
First we describe how to construct a graphical model of a biological pathway using the mEPN scheme 156 
(steps 1-8). We then explain how to convert this purely graphical representation into a resource that 157 
supports computational modelling of the system (steps 9-11). Next, we present how to test the dynamic 158 
properties of the model through running simulations and visualizing results (steps 12-20), and in the final 159 
section (steps 21-25), describe how to optimise and validate the pathway model. The workflow is shown 160 
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schematically in Figure 1. To illustrate our approach, we use a model of interferon-β signalling. The model 161 
is small and simple, but encompasses many of the basic concepts associated with pathway construction 162 
and motifs such as a negative feedback loop, a common feature of many biological systems 43. However, 163 
we encourage the examination of other larger models we have constructed, covering a range of biological 164 
systems, in order to appreciate the scale and complexity models can achieve (examples can be found at 165 
www.virtuallyimmune.com). Before embarking on model construction, users should search the literature 166 
and pathway databases, such as those listed in Table 1, for existing diagrams of their system of interest. 167 
Careful consideration should be given to the initial scope of the model, the level of detail to be 168 
represented and what the model is to be used for once constructed. For instance, given the 169 
interconnectivity of biological pathways, it is easy to begin with the aim of modelling one thing and end up 170 
spending a lot of time modelling something entirely different, because it is one way or another related to 171 
the first. Having said this, models will inevitably evolve as information is gathered and assimilated, and 172 
the journey taken is part of the reward of modelling. 173 
 174 
Materials  175 
Equipment  176 
A computer with Windows, Apple Mac or Linux operating system (preferably 64-bit), internet connection 177 
and a web browser with JavaScript enabled. The hardware configuration may limit the size of models that 178 
can be displayed within yEd, as well as when running pathway simulations within BioLayout Express3D, 179 
where it will influence the speed of simulations and the frame rate for animations of flow. We 180 
recommended >4Gb main RAM, a Dual-core CPU, NVidia GeForce / Quadro series or ATI equivalent 181 
graphics card for advanced visualization with GLSL Shaders, preferably two monitors capable of 182 
displaying at 1,600 x 1,200 resolution and a three-button mouse to aid navigation.  183 
 184 
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Equipment setup 185 
Installation of yEd Graph editor 186 
yEd is a free and intuitive software application that can be used to create high-quality network diagrams, it 187 
runs on all major platforms: Windows, Unix/Linux and Mac OS X. Download and install the latest release 188 
of the yEd Graph editor from the yWorks (Tübingen, Germany) website www.yworks.com. yEd will use up 189 
approximately 215 MB of hard disk space. If you encounter any problems with the installation of yEd 190 
contact: support@yworks.com  191 
Loading the mEPN palette 192 
Download the GraphML (.graphml) file containing the mEPN glyphs (Supplementary Data 1) and load it 193 
into yEd by selecting Edit → Manage Palette → Import Section. This will provide the standard palette of 194 
mEPN glyphs that can be selected as required when constructing a pathway model. To display the mEPN 195 
symbols palette select from the menu bar Windows → Palette. Alternatively, create each node type 196 
afresh by adding a node and changing its visual properties [F6]. As an example, see the list of 197 
components present in the interferon-β pathway (Figure 2A). 198 
Installation of BioLayout Express3D 199 
BioLayout Express3D software allows the visualization and analysis of large network graphs in two and 200 
three-dimensional space and supports the computational modelling of networks using the signalling Petri 201 
net (SPN) algorithm37. BioLayout Express3D runs on Windows, Mac OS X and Linux platforms. Java SE 6 202 
or 7 is required and can be downloaded from http://www.java.com/getjava. BioLayout will use up 203 
approximately 41 MB of hard disk space. To download the BioLayout Express3D installer, navigate to 204 
http://www.biolayout.org/download/ and download an installer for Windows (.exe) or Mac OS X (.dmg). 205 
For Linux platform use the universal JAR file that may be run without an installer. When BioLayout 206 
Express3D runs for the first time it creates a preferences file that can be changed and saved at any time 207 
from the menu option Tools → Save Preferences. Users can customize many options selecting from the 208 
menu bar Tools → General Properties (Shift+P). Further details on the software interface and its 209 
customization are available in the BioLayout Express3D manual that can be downloaded from the tools 210 
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support pages. If you encounter any problems with the installation of BioLayout Express3D contact: 211 
support@biolayout.org  212 
 213 
Procedure  214 
Pathway model construction (timing: hours to months depending on complexity 215 
of model)  216 
1. Source information for pathway construction. A pathway model should aim to provide a 217 
comprehensive and reliable view of the current state of knowledge about the system. To 218 
achieve this collect and extract the relevant information about the pathway from the literature, 219 
databases and existing diagrams. Possible sources to consult are presented in Table 1. A 220 
comprehensive list of databases for data mining can be found at www.pathguide.org. For 221 
some pathways, data are available from multiple species and/or cellular systems, therefore 222 
users must decide whether to piece together information from heterogeneous sources or to 223 
restrict their model to reflect a particular species, cell type or developmental stage. To keep 224 
track of the data, create a spreadsheet that includes: molecular identifiers, e.g. HUGO, 225 
Entrez IDs, details about nature of the molecular interactions, sources of information, e.g. 226 
PubMed ID, the quality of evidence (as assessed by number of publications supporting a 227 
given interaction and the reliability of the assays used) and any additional information that 228 
may be relevant.  229 
!Troubleshooting 230 
 231 
 232 
2. Identify the types of pathway information. Divide details of the pathway of interest into the 233 
categories defined the mEPN notation scheme (see BOX 1). Find the ‘real’ name of pathway 234 
components. The use of standard gene/protein names is essential in defining the exact 235 
identity of components, especially if models are to be used in the interpretation of omics data 236 
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where the use of standardised nomenclature systems is standard practice (see BOX 3). 237 
Record and characterise the type of interaction between components. 238 
 239 
3. Commence drawing - addition of entity nodes. Molecular components are represented using 240 
entity nodes. To add an entity node to the diagram, select and drag the appropriate glyph 241 
from the mEPN palette (BOX 1).  Edit a node’s properties by selecting it and pressing [F6]. 242 
The node Properties dialogue will appear. Add the component’s name to the General tab, 243 
where necessary changing the size of the node to fit the label, record the reference source or 244 
insert a brief description about a given component in the Data tab. Also add a hyperlink to an 245 
external site (for example NCBI’s Gene database), which can then be activated by selecting 246 
the node and pressing [F8]. A description of the component, if available, will be shown in a 247 
pop-up window when the mouse is placed over the node in yEd.  248 
 249 
4. Draw the interactions between entity nodes. The nature of an interaction between 250 
components may be represented using a combination of process nodes and edges. To add a 251 
process node to the diagram, select and drag the appropriate glyph from the mEPN palette 252 
(BOX 1). As with components (entity nodes) additional information may be added to the 253 
process node by selecting it and opening the Properties dialogue [F6]. Pathway modules are 254 
a special type of process node. They represent multi-reaction processes or events and are 255 
represented using octagons with a label identifying the name of the process they represent. 256 
They might be used to represent such pathway as signalling cascades, endocytosis, 257 
compartment fusion, etc. Edges are lines that join entity and process nodes. Edges denote 258 
the type of interaction (activation, catalysis, inhibition) and their directionality establishes 259 
inputs and outputs from entity/process nodes. To add an edge, click on a node using left 260 
mouse button and keep held down, then drag the mouse to move the edge to the target node 261 
and release. If you release the mouse button on the way to the target node, a pivot point will 262 
be introduced. To change the appearance of an edge (colour, thickness, arrow type or to add 263 
text/hyperlink), select the edge by clicking on it and open the edge properties dialogue [F6]. 264 
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The sample Interferon_components.graphml file can be used to try out the procedures 265 
described in this step (Supplementary Data 2).  266 
CRITICAL STEP yED supports the import of data in Excel or .CSV files in a variety of formats 267 
(see http://yed.yworks.com/support/ for details). This functionality may help initially in defining 268 
a set of pathway components and the interactions between them, prior to manual editing of 269 
node/edge properties and layout.[AU: Editor changed this to Critical Step as our format 270 
does not allow ‘notes’] 271 
CRITICAL STEP. In general (and absolutely so when constructing a diagram to be used for 272 
computational modelling), nodes comprising a pathway should be arranged as a bipartite 273 
graph i.e. entity nodes should be connected exclusively to a process nodes and vice versa. 274 
This structure is the same structure used by Petri nets (places must be connected to 275 
transitions) and it is essential if the model is to be used for simulation experiments. 276 
 277 
5. Add compartments. Components should be represented as existing within a given cellular 278 
compartment. Drag the desired compartment node from the mEPN palette and enlarge it to 279 
cover the section of the pathway diagram which represents a given cellular compartment 280 
such as the plasma membrane, cytoplasm or nucleus. Move the selected compartment 281 
behind the diagram by choosing Edit → Lower selection. Name the compartment, placing the 282 
name between asterisks (*compartment name*). The asterisks inform the BioLayout 283 
Express3D parser to treat these nodes differently: they are displayed as a translucent 284 
background to the pathway and cannot be selected within this tool. If they are labelled as 285 
follows *compartment*N* where *N* is a numerical value, e.g. 100, when viewed in BioLayout 286 
the compartment becomes a 3D container where the N value determines its depth (Z-value). 287 
The decision on a compartment’s ‘depth’ is based purely on final aesthetics as compartments 288 
do not effect model dynamics.  Generally the cell membrane would be the largest component 289 
and its internal organelles are smaller compartments that sit within it, but other than this the 290 
values given are subjective. Suggested cellular compartment colours are defined in the 291 
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mEPN palette. Generally, when compiling a model it is best to add compartment nodes at the 292 
end or at least put them to one side when editing, as they tend to get in the way. The 293 
completed pathway should look similar to the interferon-β pathway example in Figure 2B. 294 
 295 
6. (Optional) Add negative feedback loops. Feedback loops are network motifs common to 296 
many systems and involve the activation of a pathway component that goes on to inhibit an 297 
earlier step in the process. The inhibition of the interferon-β receptor by SOCS1 whose 298 
transcription is activated by the interferon signalling pathway represents such a negative 299 
feedback loop (Figure 2B). To represent an inhibitory activity such as this using the mEPN 300 
scheme, place an inhibitor edge from the inhibitor molecule to a process node representing 301 
the step that is inhibited.  302 
 303 
7. Optimise model layout. It is essential that a pathway model is compact and easy to follow i.e. 304 
be readable by a human. How this is best achieved will be influenced by a model’s size and 305 
complexity. First organise the pathway components based on where they reside within the 306 
cell, i.e. their cellular compartment. Then attempt to separate out ‘modules’ based on 307 
connectivity amongst a group of nodes, e.g. a particular signalling cascade or other series of 308 
events. This helps with a model’s readability and facilitates model expansion as new data 309 
becomes available. Further information on layout optimisation can be found in BOX 4. In 310 
practice, model optimisation is normally an iterative and time consuming process often 311 
requiring a degree of trial and error in how best to layout the diagram. When in the dynamic 312 
modelling phase it may for example be necessary to add in motifs that in effect delay the 313 
passage of tokens from place to another in order, to model processes that are not explicitly 314 
shown but may influence the order or timing of an event. 315 
 316 
8. Save and export the pathway models. The pathway model should now represent a 317 
diagrammatic version of known events and should be saved in the GraphML file format 318 
choosing File → Save. Within yEd a model can also be exported as an image in PNG or JPG 319 
format, as PDF or as HTML by selecting File → Export and selecting the preferred format.  320 
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 321 
Model testing - conversion of a graphical model into a computation model 322 
(timing: minutes to hours) 323 
9. Set the initial parameters. To convert a graphical representation of a pathway into a 324 
computational model, you must define the initial state of the system through a process of 325 
‘parameterisation’. To parametrise the assembled model, add defined numbers of tokens to 326 
entity nodes at the beginning of network i.e. nodes that have no ‘parents’ (upstream 327 
connections). To define the initial state of a component, place an input node (depicted as a 328 
black rectangle which functions as a transition node) upstream of the component to be 329 
parameterised and connect it with a standard edge. Define the number of tokens to be added 330 
to the node by selecting the edge between an input node and component. Open the edge 331 
properties dialogue [F6] and type the desired number of tokens into the edge name (text) 332 
(Figure 2C). Token values can in theory range from 0 to millions but in essence represent the 333 
relative amount or activity of a given component under initial conditions. Ideally, the initial 334 
parameters should be set with reference to some experimental data providing information on 335 
the relative initial concentrations of the pathway components where known. However, in the 336 
initial stages of pathway parameterisation and model testing, it is often sufficient to place an 337 
arbitrary number of tokens on components, e.g. 1000, just to check the connectivity between 338 
inputs and outputs is not compromised in any way.  339 
 340 
10. Define inhibitory reactions. An inhibitor edge originates from an inhibitory molecule and 341 
terminates at the process to be inhibited, tokens present on the inhibitor node prevent token 342 
flow through the process node[AU: Editor amended this sentence for clarity, please 343 
check.]. For details on placing inhibitory reaction see Box 5.[AU: Editor added this 344 
sentence and added the rest of the explanation in a new box, Box 5. Please check.] 345 
 346 
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 347 
11. Save the parameterised model in the GraphML file format choosing File → Save. GraphML 348 
files can be loaded directly into BioLayout Express3D. A parser within the tool translates the 349 
mEPN nodes into their 3D equivalent shapes such that they can now be visualised within the 350 
tool’s 3D environment. It also differentiates between nodes in the diagram that act as Petri 351 
net ‘places’ and that are ‘transitions’, and reads the parameterisation markings that define 352 
initial token inputs. BioLayout Express3D is also able to perform stochastic flow simulations 353 
using a modified version of the signalling Petri net algorithm37. A file containing simple Petri 354 
net models of all primary motifs found in pathways is provided as a means to better 355 
understand the flow characteristics of this algorithm (Supplementary Data 3). 356 
 357 
Running simulations using BioLayout Express3D (timing: 5-15 min) 358 
12. Load the saved GraphML file into BioLayout Express3D. Following opening of the file 359 
answer yes to the dialogue window “This looks like a Signalling Petri Net (SPN) pathway. 360 
Would you like to run a SPN simulation now?” (Figure 3A). This opens the SPN simulation 361 
dialogue (Figure 3B). The dialogue can also be selected from the main menu under the 362 
Simulation menu or by pressing the “RUN SPN” button on the sidebar. Supplementary data 363 
4 is the interferon-β pathway model shown in Figure 3C and as such is ‘simulation 364 
ready’.[AU: I placed this sentence here to prevent Figure 3C to be referenced before 365 
3A and B] 366 
!Troubleshooting 367 
 368 
13. Set the SPN simulation options. Choose the number of time blocks and the number of 369 
runs. A ‘time block’ is when all transitions are fired exactly once in a random order and 370 
tokens moved as a result. A series of time blocks is referred to as a ‘run’, the more time 371 
blocks the longer the run (Figure 3B item 1)[AU: I’ve replaced this to fit our format, as 372 
we do not allow adding a number like the ‘1’ here directly after the letter. Please 373 
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check if this is correct throughout.] The bigger the model or the more conditions you 374 
want to test within a simulation, the more time blocks you will require for a simulation. It is 375 
good practice to check the nodes furthest away from token input points to ensure that 376 
token accumulation has plateaued or in the case of negative feedback circuits, that enough 377 
time blocks have been run to evaluate the oscillatory behaviour of the system. The Petri 378 
net algorithm employed here is stochastic in nature. That is to say that the number of 379 
tokens passed on, when a transition is ‘fired’ is variable depending on the algorithms 380 
stochastic setting (see below), and furthermore the order in which transitions are fired is 381 
random. Therefore, the result of individual runs can be highly variable. For this reason a 382 
simulation is generally comprised of multiple runs, where the outcomes from individual runs 383 
are averaged to calculate the mean number of tokens present on a given node at each 384 
time block (Figure 3B item 2). The more runs used the less variable the results between 385 
simulations, but the more time it will take to perform a simulation. To visualise the variation 386 
associated with a given simulation check the ‘Calculate Variance’ and pick either standard 387 
deviation or standard error (Figure 3B item 3).  388 
 389 
14. Select the token stochasticity setting. The possible modes for token flow can be selected as 390 
shown in (Figure 3B item 4) and are described in the table below: [AU: Edited as in-text 391 
table, OK] 392 
 393 
Setting Description 
Uniform 
Distribution 
Each time a transition is fired, an entirely random number of tokens between 
zero and the maximum number of tokens are moved from an input place to 
the output place (assuming there no other inputs on the transition which may 
influence flow). This mode is as originally described by Ruths et al.37 in their 
description of the SPN algorithm. 
Standard 
Normal 
Each time a transition is fired, the number of tokens moved between input 
and end places will be randomly chosen from a standard normal distribution 
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around 50% of the number of tokens on the input place. 
Deterministic This moves exactly half of the tokens from input place to the output place 
each time a transition is fired. 
 394 
 395 
Normally we would use the standard normal distribution setting, as a halfway house between 396 
the other two modes of token flow. In some settings, the average result of simulations is 397 
similar with all these settings although variation between runs is greater with the more 398 
stochastic token flow settings, especially the uniform mode. However, when simulating 399 
feedback loops the mode of token flow can have a marked effect on the behaviour of such 400 
systems.  The mode you select may be based on which best models your system of interest.  401 
 402 
15. Selection of SPN simulation transition type. Token movement between places is via transition 403 
nodes which all operate using the same set of rules governing token flow. We have introduced 404 
two options, consumptive transitions and original transitions, which differ in how they operate 405 
with respect to token accumulation, as described in the table below (Figure 3B item 5). 406 
Generally, we use the consumptive transition mode as this prevents the accumulation of tokens 407 
on entities where there is a constant input of tokens throughout the simulation but where flow 408 
through the target transition may be intermittent. [AU: Edited as in-text table and referred to 409 
table in text above, OK] 410 
Option Description 
Consumptive 
Transitions 
Tokens are consumed from place nodes irrespective of whether the transition 
is ‘open’ or not i.e. if there are two inputs into a transition and one has tokens 
and the other does not, tokens will still be lost from the input place with 
tokens as if flow were unrestricted. 
Original 
Transitions 
Tokens accumulate on input nodes where flow from them is blocked i.e. if 
there are two inputs into a transition and one has tokens and the other does 
not, tokens will not be lost from the input with tokens. This mode was as 
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originally described by Ruths et al.37. 
 411 
 412 
15. Run the simulation. Press the ‘Run the Simulation’ button to initiate the computation of the SPN 413 
algorithm (Figure 3B item 6).  414 
Critical Step. The time it takes to run a computation depends on the number of time 415 
blocks/runs, the size of the pathway model and hardware on which the simulation is run. 416 
However, for most small to medium size pathways (10’s-100’s of entity/process nodes) and 417 
hardware configurations, the time taken is usually a few seconds or less for a typical modern 418 
laptop. 419 
!Troubleshooting 420 
 421 
16. Save the results. Once the SPN simulation algorithm has finished, a Simulation Results 422 
dialogue appears (Figure 3C). Token level per node per time block results can be saved as a 423 
.txt or .spn file by ticking the “Save SPN Results” or pressing ALT+S (Figure 3C item 7). Saved 424 
simulation results files can be loaded pressing ALT+L in the main window. .spn result files can 425 
also be opened in programs such as Excel as a spreadsheet, or viewed and edited in a text 426 
editor. An mEPN model can also be exported as a Systems Biology Graphical Notation 427 
(SBGN)44 diagram via File -> Export -> SBGN file. This can be opened in any SBGN compliant 428 
software, e.g. VANTED with SBGN-ED add-on21.  429 
17. Visualize token flow as node output graphs. To visualize the simulation results for a selected 430 
entity/place node, close the SPN simulation results dialogue (Figure 3C item 8), position the 431 
cursor over the node of interest and a pop-up window will appear showing the token flow 432 
associated with that node (Figure 3D). To view and compare token flow in multiple nodes, 433 
select the nodes of interest by pressing Shift+left mouse button and dragging the select 434 
window over the nodes of interest or by pressing the Shift+ALT+left mouse button to select 435 
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multiple nodes. The corresponding flow graphs can be viewed using the Class Viewer by 436 
pressing CTRL+C (Figure 3E) or the button with cog icon on left menu bar of the main window 437 
(Figure 3G).  438 
A range of options are available within BioLayout to adjust graph appearance. Shift+> or 439 
shift+< will increase or decrease node size, respectively; under the General tab you may turn 440 
on or off the visualisation of the compartments (yEd Graphml Container Rendering); and by 441 
pressing the ‘Render Plot to File button’ on the top of the Class viewer window the graph can 442 
be saved as .jpg or .png image file (Figure 3E item 9).  443 
18.  Visualize token flow as an animation. Open the Simulation Animation Control window (ALT 444 
+ A) when the simulation has finished (Figure 3F). Use options provided within BioLayout 445 
Express3D tool as described in the table below to control simulation visualization: [AU: 446 
Edited as in-text table and referred to table in text above] 447 
Option Description 
Node 
Animation 
(Figure 3F item 
10) 
Choose which nodes are animated (all, selected or pathway 
components only), and the type of animated transition that takes place 
between the node value associated with one time block and the next 
(discrete, linear, polynomial). 
Timing (Figure 
3F item 11) 
Define how many time blocks per second are displayed and therefore 
the speed of the animation. If necessary also define which time block 
the animation begins from. 
Size 
Transition 
(Figure 3F item 
12) 
Set maximum size of nodes during the visualization of token flow, i.e. 
when the number of tokens is at its maximum. The ‘Set (fixed) node 
value’ is the number of tokens on a node at which the maximum node 
size/colour is reached. The default value for the ‘Max value’ is 
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determined by the maximum number of tokens that accumulates on any 
node during a simulation. It is often the case that some nodes 
accumulate tokens much in excess of others, e.g. when their output is 
blocked. This can result in the majority of nodes seemingly to change 
little in size or colour during a simulation. Click on this value and add a 
value of your choice, and click on the associated check box, to maintain 
this value for subsequent runs. 
Colour Palette 
Spectrum 
Transition 
(Figure 3F item 
13) 
A number of colour palettes are available, or one can be loaded by 
user, to colour nodes so as to reflect their token value. Select colour 
spectra from dropdown menu, load your own, or more normally, use 
default. 
 448 
 449 
19. Visualize token flow as an animation. Select ‘Start Animation’ (Figure 3F item 14) to watch 450 
tokens flow through your model (Figure 3G and Supplementary Video 1). 451 
!Troubleshooting 452 
 453 
Model optimisation, parameterisation and validation (timing: days to months) 454 
20. Check for errors. Errors in a diagram’s structure (predominately a failure to adhere to the strict 455 
requirement for a bipartite graph or improper logic), can lead to bottlenecks in token flow. 456 
When the bipartite graph structure is not maintained (e.g. an entity node is directly linked to 457 
another), tokens will accumulate on the node upstream of the issue and tokens are not passed 458 
downstream of the error. Check the reactions preceding any entity node whose token output is 459 
zero (Figure 4A) and correct mistakes. Place and transition spacer nodes are available to 460 
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position between two nodes of the same type where the graphical description of events leads 461 
to this situation. Another common issue encountered is where the presence of a pathway 462 
component is under the control of the system in which it operates. This can lead to a situation 463 
whereby for component to be synthesised it needs the pathway to be active, but the pathway 464 
is not active because it requires the activity of that component. In these circumstances it may 465 
be necessary to ‘prime’ the system adding tokens to the component in question prior to 466 
beginning the simulation. Mistakes and errors in logic are easy to make, but equally easy to 467 
spot and rectify with this approach. It is normal practice to run a simulation, find out where the 468 
issues are, edit the model in yEd and rerun the simulation. There will likely be a need to repeat 469 
this process a number of times.  470 
 471 
21. Place a final transition node at the end of the line. Without a downstream transition, a 472 
component at the end of a line of flow will simply accumulate tokens (Figure 4A). A final 473 
transition node is required to dissipate tokens from such entities. Place a ‘pathway node’ at 474 
these end points by dragging and dropping from the palette to allow indication of what 475 
happens next without showing it in detail. Alternatively, a ‘sink’ node can be placed as 476 
described above to signify that a component is removed from the system, e.g., the destruction 477 
of a protein by proteosomal degradation. [AU: Editor has changed this Step to the active 478 
tense and amended it for clarity, OK] 479 
 480 
23. Amplify or reduce token flow at specific sites. To simulate the amplification or reduction of a 481 
signal at specific sites in the network, add a numeric value to a transition-to-place edge. Select 482 
the edge, press [F6] and write a number in the Text field of the edge Properties dialogue. 483 
When a transition fires, the number of tokens produced on the downstream entity will 484 
correspond to the number of input tokens multiplied by the weight of the output edge, e.g., an 485 
edge weight of 2 will result in a doubling in the number of input tokens, where as an edge 486 
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weight of 0.5 will halve the number of tokens going forward. For example, one can amplify 487 
tokens as means to model the production of numerous protein molecules from a single 488 
transcript during protein translation (Figure 4C). 489 
 490 
24. Varying token input during a simulation. To simulate variation in the level of an input signal at 491 
different time blocks of a simulation, assign tokens to an input edge (as described in Step 9) 492 
using the following notation : a-b,c;d-e,f where ‘a-b’ defines the first and last time blocks that 493 
the number of tokens ‘c’ will be added to the model and ‘d-e’ are the first and last time blocks 494 
that you would like the number of tokens ‘f’ to be added to the model. For example: 0-5,0;6-495 
15,100,16-20,0 translates into, add no tokens between time blocks 1-5, 100 tokens  between 496 
time blocks 6-15, and then remove token input until the end of the run, time block 20. Any 497 
number of these statements may be added to an input. This allows modelling of a system 498 
before and after a stimulus, or when a stimulus is transient or delayed. 499 
 500 
25. Validate the model by comparing it to experimental data. Once a model has been constructed, 501 
checked for structural errors and parameterised according to known variables, the first 502 
question is whether the model recapitulates the known activity of the system. For example, 503 
check if genes are expressed as transcriptomics data suggests, or does the flow of metabolic 504 
pathways under different conditions reflect what is known? The simulation of pathway 505 
dynamics should recapitulate the known activity of the system. If not, the obvious conclusion is 506 
the model is wrong. This could be because it is poorly constructed or parameterised, in which 507 
case the model needs improving. More interestingly, it could reflect the fact that there is part of 508 
the system that is as yet undiscovered. Once a model is working, i.e., it verifies the known 509 
characteristics of the pathway, it can be used to test known perturbations of the system e.g. 510 
the effect of knocking down/out a gene or inhibiting an enzyme. With confidence in a model’s 511 
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characteristics it is then reasonable to use it to predict the effect of perturbing it, proving 512 
results that can be tested experimentally: one of the ultimate aims of dynamic modelling. 513 
 514 
  515 
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Troubleshooting 516 
Troubleshooting information can be found in Table 2 517 
 518 
Table 2: Troubleshooting table. 519 
Step Problem Possible reason Solution 
1 Information about a 
part of the pathway is 
unavailable. 
The experiments to 
elucidate the process 
have not been done. 
Use a ‘pathway 
module’ node to 
indicate that a process 
occurs but the details 
of which are undefined.
12 BioLayout Express3D 
fails to run.  
Incompatible hardware 
or software 
configuration. 
Contact 
support@biolayout.org. 
Improve hardware 
specification. 
15 ‘Error with Vertex 
weight!’ error popup is 
shown during 
simulation. 
Token input to node(s) 
is not readable by 
software. 
Check that token input 
is numerical (token 
input can be any 
positive number, 
including decimals) at 
all token input nodes.
19 Flow stops and 
downstream nodes do 
not accumulate tokens. 
 
 
 
 
 
Node accumulates 
tokens at linear rate.
  
 
 
Token flow occurs, but 
the size of nodes 
changes little. 
Bipartite graph 
structure has not been 
adhered to. 
 
 
 
 
 
Node has no output. 
 
 
 
 
The maximum token 
value is set too high. 
Identify bottleneck 
node by watching 
BioLayout flow 
animation. Return to 
yEd graph to edit 
model and rerun. 
 
 
Return to yEd graph to 
add sink node or other 
transition to node 
accumulating tokens. 
 
Open Animation 
Control window and 
lower value in ‘Set Max 
Value’ dialogue box.
 520 
  521 
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Timing  522 
Steps 1 to 8, Information mining and pathway construction: Hours to months 523 
Steps 9 to 11, Conversion of the graphical model into a computable format: Minutes to hours 524 
Steps 12 to 19, Visualization of pathway and running simulations using BioLayout Express3D: 5 to 15 525 
minutes 526 
Steps 20 to 25, Model optimisation and parameterisation: Days to months  527 
 528 
Anticipated Results 529 
This protocol describes the generation of pathway models using the mEPN language for graphically 530 
representing biological systems. Graphical models can be used both as a resource to store and display 531 
what is known about a pathway and can be considered an end point in their own right, that can be 532 
updated or extended as new information becomes available. In addition, they can be converted to a 533 
computational model by setting parameters to define the initial state of the pathway. Using the sample 534 
interferon-β components GraphML file (Supplementary Data 2) a pathway model can be produced that 535 
represents events from the binding of interferon-β to its receptor and the signalling pathway leading the 536 
activation of target genes. The resulting model can be parameterised by adding tokens to obtain a 537 
simulation-ready model (Supplementary Video 1). This is a relatively small diagram; we also provide a 538 
model of the hedgehog signalling pathway as an example of a larger model (Supplementary Data 539 
5)[AU: Editor changed this to Supp. Data 5, as it is mentioned after 4]. This was produced as part 540 
of a 10 week elective course by an undergraduate student with no previous modelling experience, 541 
indicating our modelling scheme can easily be performed by biologists with no prior modelling 542 
knowledge. Other pathway models are available at: www.virtuallyimmune.com.   543 
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The BioLayout Express3D software is fully compatible with the mEPN notation and can be used for 544 
pathway visualization and to perform stochastic flow simulations using a modified version of SPN 545 
algorithm37. Running simulations provides insights into the dynamic behaviour of the system by 546 
enabling users to visualize the signal flow within the network. The signal flow is simulated by the 547 
accumulation of tokens at entity nodes (places) and can be visualized in 2D graphs (as seen in Figure 548 
4) or by 3D animation (as seen in Supplementary Video 1). The inflation and contraction of the entity 549 
nodes represents the accumulation and degradation of reactants in the pathway. In this way, complex 550 
biological processes with multiple components can be modelled. 551 
 552 
The interferon-β signalling network - a feedback control system 553 
Biological systems display a variety of dynamic behaviours ranging from stable steady states to 554 
oscillations. Oscillations in protein concentrations or gene expression levels are commonly associated 555 
with the presence of negative feedback loop(s) in the regulatory network45. Based on the analyses 556 
performed using this system many factors can affect the amplitude, frequency and stability of oscillations. 557 
For instance, the time-delay (path length) between token input and inhibitor, the type of inhibition edge 558 
used (competitive or non-competitive), the number of inhibitors present and their half-life, may all affect 559 
how a model containing a negative feedback loop will operate in practice. 560 
As an example, the simple model of the interferon-β signalling pathway is presented. Interferon-β is a 561 
cytokine released by immune cells in response to pathogens. It acts as an autocrine and paracrine 562 
signalling system that triggers the activation of host defence systems. In the provided model it operates 563 
as a damped oscillator46, where low-dose IFN stimulation yields oscillations of lesser amplitude that are 564 
damped faster than those induced at a high-dose (Figure 5). To reproduce these observations users can 565 
look at the different versions of IFN signalling feedback model provided in Supplementary Data 6 [AU: 566 
Editor changed this to Supp. Data 6].  or modify the token input or topology of the Petri net examples 567 
provided in Supplementary Data 3. 568 
 569 
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Contributions of the authors: A.L., L.O’H., M.E.P developed and wrote the protocol based on their 570 
experience in using the approach for modelling their own pathway systems of interest, T.A. developed a 571 
number of the features within BioLayout Express3D including SBGN export and refinement of the Petri net 572 
algorithm, D.W. developed and has helped maintain the VirtuallyImmune.org website that is associated 573 
with this work, and L.B.S. helped with writing and editing the manuscript. T.C.F. has lead the 574 
development of the mEPN notation scheme and its use in modelling a variety of pathway systems; 575 
oversaw the implementation of model import into BioLayout Express3D; model visualisation within this tool, 576 
refactoring and refinement of the Petri net algorithm, and conceived of and assisted in writing the paper.  577 
 578 
Figure legends 579 
Figure 1. Workflow with steps described in the Procedure. 580 
Figure 2. Construction of a simple pathway model describing type-1 interferon signalling. (A) 581 
Components of the interferon-β signalling pathway drawn using mEPN notation (BOX 1). The information 582 
necessary to construct the interferon-β pathway has been highlighted in the pathway description: entity 583 
and transition nodes, edges and cellular compartments. (B) interferon-β pathway diagram assembled in 584 
yEd software using the pathway parts shown in A. (C) Parameterisation of interferon-β pathway by the 585 
addition of token inputs and a sink node output on SOCS1 inhibitor node (highlighted by red rectangles). 586 
Also shown is the edge properties dialogue in yEd where tokens can be added to an input edge. Model 587 
adapted from O’Hara et al., 2016 1. 588 
Figure 3. Visualization of token flow. (A) When a model is loaded into BioLayout Express3D it is 589 
displayed in a 3D environment using 3D equivalents to the 2D node glyphs as rendered in yEd. The 590 
software automatically recognizes a diagram as having been parameterised for computational modelling 591 
(based on the presence of process nodes as defined in the notation system) and prompts users to run a 592 
SPN simulation. (B) In the SPN Simulation dialogue users can set constraints on how to run the SPN 593 
simulation algorithm. (1) Defines the number of time blocks in a simulation; (2) Defines the number of 594 
runs in a simulation; (3) Calculates the variance in token flow between runs; (4) Defines the nature of the 595 
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stochastic flow of tokens; (5) Defines the rules governing token flow through transitions; (6) Run the 596 
simulation. (C) SPN Simulation Results dialogue box summarises the simulation. (7) SPN results may be 597 
saved before the user chooses to (8) run the simulation again, close the dialogue box or proceed to 598 
animate the simulation. (D) After a simulation has been run token accumulation at specific nodes can be 599 
visualised by placing the cursor over the node. (E) The flow of tokens across one or a number of selected 600 
nodes can be plotted using the Class Viewer showing plots of token flow over the time course of the 601 
experiment for selected nodes. The name and class of selected nodes is also displayed, and below are a 602 
range of options available for node selection and data export. (9) The token plot can be saved as a .png 603 
or .jpg image file. (F) Animation Control dialogue. (10) Options for the type of nodes to be animated and 604 
interpolation of flow between time bocks; (11) Speed of animation (time blocks per second); (12) Node 605 
size at maximum token number; (13) Colour palette selection to highlight change in token number; (14) 606 
Animation control: start, pause, step, stop. (G) BioLayout Express3D can produce animations of token flow 607 
through the model across time blocks. Node size will increase/decrease depending on the number of 608 
tokens passing through them and the colour of the node will also change according to a predefined 609 
spectrum of colours.  610 
Figure 4. Influencing token flow along a linear pathway. Figure shows the flow of tokens through a 611 
small linear pathway motif depicting a gene being transcribed into mRNA, which is then translated into the 612 
encoded protein. Addition of a sink node represents the protein’s degradation. (A)  Blocked flow. Top of 613 
the three illustrations all is as described above, and over the 20 time blocks of the simulation there is an 614 
initial rise in the level of the protein followed by a steady-state, as the number of tokens entering the entity 615 
node matches those leaving through the sink i.e. the rate of production of the protein matches the rate of 616 
its degradation (blue line). Failure to maintain bipartite graph structure (shown here by connecting two 617 
entity nodes for mRNA and protein without a process node between them) causes tokens to accumulate 618 
on the first entity node (mRNA) and not pass to the second (protein), which stays at zero tokens 619 
throughout the simulation (pink line). In the absence of a sink node, tokens to accumulate on the protein 620 
node (green line). (B) Modelling time. The diagrams show the effect of increasing the length of linear 621 
networks on the rate of token accumulation. Input tokens are introduced into each of the networks at the 622 
same time but the protein accumulates at different rates. The delay is proportional to the number of 623 
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transition steps introduced in the network and such delay motifs may be added where a transition nodes 624 
represents a multistep process such as transcription or translation.  (C) Amplifying or depleting signal. 625 
The addition of a value to the edge leaving a transition can be used increase (pink line) or decrease 626 
(green line) downstream token flow. In this way one might model one mRNA molecule leading to 627 
production of multiple protein molecules, or the inefficient translation of mRNA where only a single protein 628 
molecule is produced from multiple mRNAs. Simulation options in A, B and C: 100 tokens, 100 runs, 20 629 
time blocks, Normal Standard distribution and with standard deviation of token flow between runs shown. 630 
Figure 5: Effect of parameterisation on activity of feedback loop. (A) A simple pathway model 631 
representing the type-1 interferon signalling pathway constructed and parameterized in yED using mEPN. 632 
Graphs show token accumulation on the activated transcription complex ISGF3 (circled in red) following 633 
simulations with (B) 1000 input tokens (blue line) or 100 input tokens (green line) added to interferon-β 634 
with SOCS1 acting as a non-competitive inhibitor or (C) as a competitive inhibitor of the activated receptor 635 
(dashed red edges). (D) Oscillatory activity of the SOCS1 feedback loop with (magenta line) or without 636 
(blue line) a delay introduced between the transcription and translation of SOCS1 (dashed black edges), 637 
again with SOCS1 acting as a non-competitive or (E) competitive inhibitor of the activated receptor. 638 
Simulation options: 100 runs, 500 time blocks, Normal Standard distribution and with standard deviation 639 
of token flow between runs shown. 640 
 641 
  642 
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Supplementary Files 643 
Supplementary Data 1.  mEPN palette for loading within yEd software. This is a graphml file containing 644 
all the different types of entity nodes to represent the different classes of molecules that might play a part 645 
in a pathway, as well as the process nodes that represent different types of interactions. This file can be 646 
loaded into yEd to provide a palette of mEPN nodes for pathway construction (see step 4 of the 647 
procedure). 648 
Supplementary Data 2.  Interferon-β signalling pathway components. This is a graphml file containing all 649 
the different parts of the simple model shown in figure 2B, to allow practicing model construction. Try 650 
assembling the model using only the text below: ‘Interferon B (IFNB1) is a cytokine released from many 651 
cell types in response to immune stimulation. It homodimerises and binds to its cell surface receptor 652 
complex composed of the receptor proteins IFNAR1 and IFNAR2 and the intracellular kinases TYK2 and 653 
JAK1.  The complex is composed of 2 of each of these proteins. Binding causes a conformation change 654 
in the complex resulting in the autophosphorylation of JAK1. Once activated, the complex catalyses the 655 
phosphorylation of STAT2 which forms a heterodimer with STAT1. This complex then binds interferon 656 
regulatory factor 9 (IRF9), forming the complex often referred to as ISGF3, and translocates to the 657 
nucleus.  Here it binds to the IRF sequence in the promotor of a number of genes including MX1, MX2, 658 
IFIT1, IFITM3, TAP1, OAS1, GBP1, PSMB9, SOCS1. In turn SOCS1 inhibits the autophosphorylation of 659 
the receptor thereby inhibiting further activation.’  660 
Supplementary Data 3.  Primary network motifs drawn in Petri net style for testing SPN algorithm. This is 661 
a graphml file containing a series of different network motifs and parameterisations potentially found in 662 
pathway diagrams. This includes linear networks, multiple inputs/outputs to transitions and nodes, and a 663 
series of models representing a range of feedback loops with varying path lengths between token input 664 
and inhibition, inhibition type (competitive vs. non-competitive), and one or multiple feedback inhibitors. 665 
The file is designed to allow you to explore the different interaction types and algorithm settings when 666 
setting up a simulation run. Certain nodes are coloured such that when a simulation has been run within 667 
BioLayout, these nodes may be selected and you can compare results across motifs. 668 
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Supplementary Data 4.  Interferon-β signalling pathway. This is a graphml file of the simple model 669 
shown in figure 2B.   670 
Supplementary Data 5.  Example of a more complex model - Hedgehog signalling pathway. This model 671 
(given here as graphml file) is a representation of Hedgehog signalling from the binding at its receptor, 672 
activation of the GLI protein on the tip of the primary cilium through the activation of various downstream 673 
pathways (not shown in detail). It contains 550 nodes and 601 edges and was assembled using pathway 674 
resources such as Reactome22 and the primary literature. Its parameterisation, in terms of token 675 
placement is arbitrary.  676 
 677 
Supplementary Data 6.  Changing parameters - Interferon-β signalling pathway. This is a graphml file 678 
containing six versions of the model shown figure 2B (Supplementary Data 4), each version is 679 
parameterised slightly differently, with variation in: type of inhibition (competitive vs. non-competitive); 680 
introduction of a delay between SOCs1 expression and protein; and an amplification of signal between 681 
gene and mRNA.   682 
 683 
Supplementary Video 1. Movie of the interferon-β signalling pathway (Supplementary Data 4) simulation 684 
run within BioLayout. The movie shows the process of model loading, running the simulation, inspecting 685 
token accumulation on specific components and watching the flow of tokens run through the model as an 686 
animation. 687 
 688 
 689 
 690 
 691 
  692 
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BOX 1: mEPN Notation 2017 693 
The modified Edinburgh Pathway Notation (mEPN) scheme3 is a graphical notation system based on the 694 
concepts of the process diagram4, below the glyph library is shown in its current form (reproduced from 695 
O’Hara et al. 1). 696 
[CE: Please place ‘Box 1 Figure’ here] 697 
 698 
Pathway components 699 
Types of pathway information. The information depicted in a pathway diagram drawn using the mEPN 700 
scheme may be divided into the following categories: 701 
• Entity: any component involved in a pathway, e.g. protein, protein complex, nucleic acid 702 
sequence (promoter, gene, RNA), simple biochemical, drug etc., and depicted as an ‘entity node’. 703 
Different shaped nodes are used to represent different types of components. The mEPN scheme 704 
consists of twelve different entity nodes (detailed in the top left panel). Also included are a 705 
Boolean logic ‘OR’ operator node and spacer node (represented as a white circle with a black 706 
border) that may be required to maintain bipartite pathway arrangement. Entity nodes function as 707 
the equivalent of Petri net ‘places’ and all entity nodes are equivalent in Petri net simulations 708 
• Process: an interaction that occurs between pathway components, where one component 709 
interacts with or influences the state of another through its binding, inhibition, catalytic conversion, 710 
etc., is depicted as a process node. Processes are generally depicted as a circular node with a 1-711 
3 letter code to indicate the type of process, e.g., P = phosphorylation, B = binds, X =cleavage 712 
etc. Included in the scheme are 38 different process nodes (top central panel). Additional to 713 
these, but also acting as transitions, are a sink node which is placed at the end of pathway and 714 
represents removal of a component from the system; a pathway module node that summarises 715 
not one process but a series of events; a Boolean logic ‘AND’ operator node; token input nodes 716 
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that are placed at the start of a pathway and oriented either horizontally or vertically to fit in with 717 
the pathway layout; a spacer node represented as a black diamond. A larger version of this node 718 
can also be used as a distribution node when multiple edges exit from an entity node. Process 719 
nodes function as the equivalent of Petri net ‘transitions’ and all process nodes are equivalent in 720 
Petri net simulations. 721 
• Interaction: a directional edge that links an entity node to a process node or vice versa that 722 
indicates direction and the nature of the interaction. There are six possible connecting edges 723 
(bottom central panel) that represent the nature of the interaction between nodes. The first three 724 
(interaction, catalysis and action potential) operate identically within a Petri net and serve to carry 725 
tokens between entity and process nodes. The two inhibitor edges act to inhibit the flow of tokens 726 
through target process nodes albeit based upon different rules. The non-competitive inhibitor 727 
edge completely blocks token flow through the target transmission if any tokens are present on 728 
the inhibitor node. In contrast the competitive inhibitor edge works by deducting the number of 729 
tokens residing on the inhibitor away from the number of tokens flowing through the target 730 
transition. Finally, the non-covalent interaction edge can be used to depict two separate entities 731 
within a complex. This may be a useful when describing large complexes, but these edges do not 732 
operate within the context of a Petri net simulation.  733 
• Cellular compartment: define where pathway components reside and interactions take place, 734 
such as an organelle (e.g. mitochondrion, nucleus) or a transient cellular compartment (e.g. 735 
vesicle). In the diagrams they are shown as large coloured nodes that sit behind the interaction 736 
model (right panel). 737 
End of Box 1 738 
 739 
  740 
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BOX 2: Petri nets to model biological systems 741 
Petri nets (top panel) are a mathematical approach for describing distributed systems and have been 742 
used extensively in the modelling of many different kinds of systems including biological pathways. There 743 
are numerous types of Petri net algorithms and software that support modelling using them. The Petri net 744 
algorithm employed here was first developed and described by Ruths el al.37, a modification of a 745 
synchronized Petri net model and firing policy, they called the signalling Petri net (SPN). Petri nets share 746 
a number of common features. Models are constructed as directional bipartite networks where nodes are 747 
considered to be either ‘places’ or ‘transitions’ connected by ‘arcs’. Places usually represent an entity or 748 
state and by convention are represented as a white circle. Transitions represent interactions between 749 
entities or the transition of an entity from one state to another and are usually represented as a black 750 
rectangle. Arcs are directional arrows that connect places to transitions and vice versa. The availability of 751 
an entity and its abundance can be represented by the initial placement of tokens. The flow of information 752 
through the network is represented using tokens that move between places through transitions, following 753 
in the direction of the arcs. In the context of biological pathways paces represent pathway components, 754 
transitions correspond to processes that modify the components in some way, such as phosphorylation, 755 
binding etc., and are referred to as ‘process nodes’. The interactions between molecules are depicted by 756 
edges, equivalent to arcs in Petri net parlance. The bottom panel shows how the notation for representing 757 
pathways using mEPN map on to Petri nets. [AU: Editor edited the references to panels to refer to 758 
the updated figure, please check] 759 
 760 
[CE: Please place ‘Box 2 Figure’ here] 761 
 762 
Rules determining token flow through transitions. Activity flow is represented by the movement of 763 
tokens between places. The state of each place (component) is determined by the number of tokens held 764 
by it. When a transition is fired, tokens are moved from each input place and redistributed downstream, 765 
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the transition acting as rule-based controller of flow. A transition will pass on tokens only if all the input 766 
places contain tokens and where one input has less tokens than others, the passage of tokens will be 767 
governed by the input place holding the least number of tokens. In the case of the Petri net algorithm 768 
employed here, the movement of tokens is also stochastic.  This is because during a time block all 769 
transitions in a model are fired once but in a random order, and the number of tokens taken forward when 770 
a transition is fired will be a random number between zero and the maximum available (although we have 771 
implemented other versions of this rule, see step 13). Due to the stochastic nature of token flow, a 772 
simulation usually comprises of a number of runs, the answer being based on the average token flow 773 
across runs. Furthermore, when a transition is fired the number of tokens moved forward through the 774 
transition will be subtracted from the amount available on the input places. One innovation not found in 775 
most other Petri net simulators, is our implementation of a consumptive transition mode. When running in 776 
this mode (for us this is standard), a constant input of tokens is applied to an entity node throughout a 777 
simulation, but token levels on the node remain constant (unless others are fed in from another source), 778 
as tokens are lost from it at the same rate they are added even when there is no flow through the target 779 
transition. In this way places representing entities such as enzymes (or indeed any other molecule) can 780 
receive a constant input of tokens throughout a simulation without accumulating or losing tokens.  781 
Modelling time. Time in Petri nets is measured in abstract units called time blocks. When constructing a 782 
model, it is useful to consider how many experimental seconds, minutes, or hours correspond to a time 783 
block. Timing depends on the network topology and the further away a node is from the start of flow the 784 
longer it will take tokens to reach it. To simulate such time delays users can create a linear network that 785 
alternates transitions with spacer nodes multiple times. When tokens are passed through such a linear 786 
network the number of output tokens corresponds to the input but the time taken for tokens to reach the 787 
end is proportional to the number of spacer nodes (Figure 4B). 788 
 End of Box 2 789 
 790 
 791 
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BOX 3: Component Annotation 794 
Multiple names are frequently employed to describe molecular species.  This is particularly the case for 795 
one of the main components of biological pathways: proteins. Any given protein may be referred to in the 796 
literature by a number of different names concurrently. The use of non-standard nomenclature frequently 797 
leads to confusion in written texts and diagrams. If the naming of pathway components is not clear, then 798 
uncertainty arises as to what exactly is being depicted in a diagram and it ends up representing little more 799 
than a series of abstract concepts.  800 
Our models have generally been focused on human pathways and we have used standard Human Gene 801 
Nomenclature Committee (HGNC) names to label nodes representing genes and proteins 802 
(www.genenames.org). This and related nomenclature systems such as the Mouse Genome Database 803 
(MGD) standard (http://www.informatics.jax.org/mgihome/nomen/), now provide a near complete 804 
annotation of all human and mouse genes, and their use in the naming of proteins provides a direct link 805 
between the identity of the gene and the corresponding protein. Of course, not everyone has adopted 806 
these naming systems so where other names (aliases) are in common use, these names are often 807 
included as part of the node’s label after the official gene symbol in rounded brackets, but generally only 808 
on its first appearance in the pathway. Use of standard nomenclature also assists in the comparison and 809 
overlay of experimental data (which is usually annotated using standard gene nomenclature) onto 810 
pathway models. At the present time there are no standard and universally recognized nomenclature 811 
systems available for naming certain types of pathway components. For instance, protein isoforms tend to 812 
be named in an ad hoc manner by those who study them, and biochemical compounds are known by 813 
both their common names or by names that reflect their chemical composition. The IUPAC 814 
(www.iupac.org/) provides a standard nomenclature system for organic chemicals, but most names would 815 
have little relevance to a biologist. In cases such as these, the important thing is to be consistent and, 816 
where possible, to cross-reference the component’s ID to other sources such that the identity of the 817 
component depicted, where at all possible, is unambiguous. We have used the excellent ChemSpider 818 
resource (www.chemspider.com/) as a reference for the naming of biochemical entities, although other 819 
resources, e.g., ChEMBL (www.ebi.ac.uk/chembl/) are potentially equally good. Using the node 820 
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properties dialogue [F6], nodes may be hyperlinked to external web resources and additional notes to 821 
nodes can be added using in the Data tab within yEd. 822 
 823 
Protein state: The particular ‘state’ of an individual protein may determine its functional activity. With 824 
mEPN, a component’s state is indicated as a text addition to the node label using square brackets 825 
following the component’s name; each modification being placed in separate brackets. The system can 826 
be used to describe a wide range of protein modifications like phosphorylation [P], acetylation [Ac], 827 
ubiquitination [Ub] etc., and where details of the site of modification are known this may be represented, 828 
e.g., [P@L232] = phosphorylation at leucine 232.  829 
 830 
Protein complexes: Names of the components are given as a concatenation of the proteins belonging to 831 
the complex, separated by a colon. If a complex is commonly referred to by a generic name this may be 832 
shown below the constituent parts in rounded brackets. Where a specific protein is present multiple times 833 
within a complex, this may be represented by placing the number of times the protein is present within the 834 
complex in angle brackets i.e., <n>. A node representing a component may be coloured to impart visual 835 
information on the component’s type, e.g. to differentiate between a protein and a complex. Similarly, 836 
other types of pathway components may be represented using a range of shapes and colours – see 837 
palette (BOX 1, downloadable as Supplementary Data 1) for list of glyphs used to represent different 838 
entity types. A component may only be shown once in any given cellular compartment (in a given state). 839 
A component may however alter from one state to another, e.g., inactive to active, unbound to bound, in 840 
which case both forms are represented as separate entities. A different state may be indicated by 841 
including the name in square brackets, as described above. 842 
 843 
End of Box 3 844 
 845 
  846 
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BOX 4: Layout Optimisation 847 
There is a part of pathway modelling that could be considered art, or at least creative cartography. When 848 
starting a diagram the number of components is small, and visual comprehension of the system of nodes 849 
and edges is relatively easy. However, this situation soon changes as a diagram grows, and one of the 850 
greatest challenges is to render the inherently complex connections between components of a network 851 
model in a human readable form. This necessitates the careful placement of nodes and edges in the 852 
network layout. There are large number of layout algorithms available for network visualization but 853 
unfortunately none come close to the results achievable by a skilled human curator. Certain rules can be 854 
applied to this process to aid readability of the model: 855 
• Models should be constructed, where possible, along a horizontal or vertical axis, arranged top down 856 
or left to right in the direction of information flow. 857 
• Nodes should be evenly spaced and aligned along the chosen axis of layout but within the cellular 858 
compartment in which they reside. 859 
• Crossing over of edges should be kept to a minimum and changes in edges direction should be 860 
avoided when possible. When multiple edges run parallel to each other it is important to keep the 861 
lines straight to maintain an easy-to-follow diagram. 862 
• Space can be organised effectively by structuring sub-pathways into modules. 863 
• Modules of the pathway should be arranged so that the connected glyphs are in close proximity, to 864 
minimise overlapping of connective edges. 865 
• Hierarchical relationships between components should be shown in the layout of interactions. To do 866 
this, an orientation of pathway flow is chosen (e.g. left to right or top to bottom) and should be 867 
maintained throughout the diagram where possible.  868 
However, each diagram is essentially unique and each comes with its own challenges. There is no one 869 
solution that fits all models so the layout of the diagram must be able to be easily adapted to take in new 870 
components and concepts whilst maintaining its readability.  871 
 872 
End of Box 4 873 
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*START OF BOX 5* 874 
BOX 5 [AU: Please add a title] 875 
During a simulation tokens will not be lost through an inhibitor edge and therefore tokens 876 
accumulate on an inhibitor node and irrevocably block the process to which it is connected. 877 
However, if a sink node is connected to the inhibitor it serves to give the inhibitory molecule a 878 
‘half-life’ (in practice any process node will serve the same purpose, but use of the sink node 879 
helps visually define the process involved). In the absence of further input into the inhibitor 880 
node, such as during the ‘off phase’ of negative feedback system, tokens will now be lost 881 
from the inhibitor. The result is that its inhibitory effect will lessen and the blocked transition 882 
will eventually open and tokens may flow again through it. In presence of a constant input this 883 
can cause token flow in negative feedback systems to oscillate. There are two types of 884 
inhibitor edge included in the notation scheme that perform differently in the modelling 885 
environment; the non-competitive inhibitor edge (red with perpendicular bar at end) and a 886 
competitive inhibition edge (red with open diamond end). The non-competitive inhibitor edge 887 
completely blocks token flow through the target transmission if any tokens are present on the 888 
inhibitor node. In contrast the competitive inhibitor edge works by deducting the number of 889 
tokens residing on the inhibitor away from the number of tokens flowing through the target 890 
transition. The behaviour of negative feedback systems is not only dependent on the type of 891 
inhibitor edge used but also the distance between the input of tokens and the inhibitory step. 892 
The greater the distance the more tokens are able to accumulate in the system and the 893 
greater the time taken between the opening and closing of the inhibited transition, i.e., the 894 
longer the wavelength and the higher the amplitude of the oscillating signal. Other factors that 895 
can affect the oscillatory behaviour of the feedback loop are the number of inhibitors acting 896 
on the pathway and assumptions about the stochasticity of token flow. 897 
 898 
*END OF BOX 5* 899 
900 
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BOX 6: Glossary [AU: Please reference this box in the main text, as all 901 
boxes have to be referred to in the main text. I’ve also made this Box 902 
6, as I’ve made a new Box 5.]  903 
• Arc: By convention in Petri net parlance, arcs are the directional edges that connect a place to a 904 
transition or vice versa, (but never between places or between transitions). Arcs are referred to as 905 
edges in mEPN.  906 
• Edge: In mEPN notation, edge is used to refer to any line used to connect entity and process 907 
nodes to indicate an interaction (activating or inhibitory), and also the direction of that interaction. 908 
The Petri net equivalent is an arc.  909 
• Entity node: Entity nodes are glyphs that represent pathway components such as molecules or 910 
genes. The Petri net equivalent is a place. 911 
• Glyph: a visual representation of an entity, process or transition node. 912 
• GraphML: a XML-based file format used to describe the structural and visual properties of a 913 
model.  914 
• Layout: the way in which nodes and edges are set out in 2D or 3D space (physical topology). 915 
• Model: the visual representation of a network.  916 
• mEPN: modified Edinburgh Pathway Notation scheme is a graphical notation system based on 917 
the concepts of the process diagram.  918 
• Network: a number of nodes connected by edges. 919 
• Notation scheme: a system of symbols used to represent biological entities and interactions 920 
between them in a semantically and visually unambiguous manner. 921 
• Parameterization: defining the initial state of the system through the placement of tokens. 922 
• Petri net: a directed bipartite graph that alternates places (entities) and transitions (events that 923 
occur). 924 
• Place: In Petri nets, places represent possible states of the system. They are referred to as 925 
entity nodes in mEPN notation. 926 
• Process diagram: a diagram used to formally describe the components of a system, their 927 
activation state and the interactions between them. 928 
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• Process node: In mEPN notation, process nodes are glyphs that represent and define 929 
interactions between entities or the transition of an entity from one state to another. The Petri net 930 
equivalent is a transition. 931 
• SPN: Signalling Petri Net as defined by Ruths et al 37. Please note, in the context of Petri nets 932 
SPN is also often used to refer to Stochastic Petri Nets, a class of Petri net algorithms used to 933 
model the stochastic flow of tokens, as in the case here. 934 
• Tokens: Tokens represent quantitative information that is introduced and distributed through a 935 
Petri net. Here they can be thought of representing the amount and/or activity of a pathway 936 
component. 937 
• Topology: arrangement of various elements of the pathway (nodes, edges, etc.) that illustrates 938 
how information flows within the network.  939 
• Transition: In Petri nets, transitions are events or actions. They are represented as process 940 
nodes in mEPN notation. 941 
 942 
End of Box 6 943 
 944 
  945 
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Table 1: A list of resources useful for the compilation of pathway diagrams  957 
Literature Databases 
 
NCBI Pubmed http://www.ncbi.nlm.nih.gov/pubmed/ 
Web of Science http://wok.mimas.ac.uk/ 
Google Scholar http://scholar.google.co.uk/ 
Scopus http://www.scopus.com/ 
iHop http://www.ihop-net.org/ 
Component Annotation 
 
NCBI Entrez Gene http://www.ncbi.nlm.nih.gov/sites/entrez 
Gene Cards http://www.genecards.org/ 
Gene Ontology http://www.geneontology.org/GO.downloads.annotations.shtml 
PubChem http://pubchem.ncbi.nlm.nih.gov/ 
Chemspider http://www.chemspider.com 
Interaction Databases 
 
ConsensusPathDB http://cpdb.molgen.mpg.de/ 
BioGRID http://thebiogrid.org/ 
IntAct http://www.ebi.ac.uk/intact/ 
GeneMANIA http://www.genemania.org/ 
Human Protein Reference 
Database 
http://www.hprd.org/index_html  
MINT http://mint.bio.uniroma2.it/mint/Welcome.do  
STRING http://string-db.org/ 
DIP http://dip.doe-mbi.ucla.edu/dip/Main.cgi  
MIPS CORUM http://mips.helmholtz-muenchen.de/genre/proj/corum 
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Pathway Repositories 
 
KEGG http://www.genome.jp/kegg/ 
Reactome http://www.reactome.org/ 
Biocarta http://www.biocarta.com/genes/index.asp  
WikiPathways http://wikipathways.org/index.php/WikiPathways  
 958 
  959 
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